{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T02:30:31Z","timestamp":1783996231996,"version":"3.55.0"},"reference-count":132,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revue Neurologique"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1016\/j.neurol.2020.02.011","type":"journal-article","created":{"date-parts":[[2020,9,5]],"date-time":"2020-09-05T22:41:21Z","timestamp":1599345681000},"page":"804-822","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Urinary tract infections and multiple sclerosis: Recommendations from the French Multiple Sclerosis Society"],"prefix":"10.1016","volume":"176","author":[{"given":"C.","family":"Donz\u00e9","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Papeix","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Lebrun-Frenay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Donz\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Papeix","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Lebrun-Fr\u00e9nay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Collongues","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"de Seze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Dinh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Even","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Scheiber-Nogueira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Bensa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Bourre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Carra-Dalli\u00e8re","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Ciron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.M.","family":"Guennoc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Louapre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Lebreton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Michel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Maillart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Audoin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X.","family":"Ayrignac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Bernady","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Brochet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Clavelou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Colamarino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Declemy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"de Seze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Derache","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.-M.","family":"Faucheux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Heinzlef","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Labauge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Laplaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Lepage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Leray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Magy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Mathey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Mekies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Mondain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Planque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Pelletier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Pittion","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Stankhof","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Tournaire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Thouvenot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Vukusic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Wiertlevski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Zephir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Alchaar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Androdias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Benazet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Bensmail","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Biotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Blanchard-Dauphin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Bonnan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Bouti\u00e8re","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Branger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Bresch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.-P.","family":"Bru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.-P.","family":"Camdessanch\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Castel Canal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Coustans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Casez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Castan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Creange","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Creisson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"De Broucker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Depaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X.","family":"Douay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Dulau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Durand-Dubief","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Fagniez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Faucher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Floch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Fournier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Fromont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Gallien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X.","family":"Gam\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Gault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Gayou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Giroux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Gout","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Grimaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Hautecoeur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Kerbrat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Kremer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Kwiatkowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Labeyrie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Lachaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Lanctin-Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Lanotte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Manchon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Maurousset","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Michel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.-M.","family":"Milor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X.","family":"Moisset","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Mont-Cuquet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Moreau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.-C.","family":"Ouallet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Patry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Peaureaux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.-C.","family":"Pouget","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Pourcher Martinez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Radot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Ruet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Saint-Val","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Salmon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Taithe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Tatevin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Vaillant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.-P.","family":"Stahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Vuoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Zaenker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neurol.2020.02.011_bib0665","first-page":"CD007182","article-title":"Antimicrobial agents for treating uncomplicated urinary tract infection in women","volume":"10","author":"Zalmanovici","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.neurol.2020.02.011_bib0670","series-title":"SPILF","year":"2015"},{"issue":"3","key":"10.1016\/j.neurol.2020.02.011_bib0675","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1093\/gerona\/56.3.M146","article-title":"Frailty in older adults: evidence for a phenotype","volume":"56A","author":"Fried","year":"2001","journal-title":"J Gerontol"},{"key":"10.1016\/j.neurol.2020.02.011_bib0680","doi-asserted-by":"crossref","DOI":"10.1177\/1756286419878340","article-title":"Reduced serum immunoglobulin G concentrations in multiple sclerosis: prevalence and association with disease-modifying therapy and disease course","volume":"12","author":"Zoehner","year":"2019","journal-title":"Ther Adv Neurol Disord"},{"key":"10.1016\/j.neurol.2020.02.011_bib0685","series-title":"SPILF","year":"2002"},{"key":"10.1016\/j.neurol.2020.02.011_bib0690","series-title":"RCP IUAS","year":"2015"},{"key":"10.1016\/j.neurol.2020.02.011_bib0695","series-title":"EAU guidelines","year":"2018"},{"issue":"7","key":"10.1016\/j.neurol.2020.02.011_bib0700","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1177\/1352458506075651","article-title":"The neurogenic bladder in multiple sclerosis: review of the literature and proposal of management guidelines","volume":"13","author":"De S\u00e8ze","year":"2007","journal-title":"Mult Scler"},{"key":"10.1016\/j.neurol.2020.02.011_bib0705","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/nrurol.2016.53","article-title":"Management of neurogenic bladder in patients with multiple sclerosis","volume":"13","author":"Ph\u00e9","year":"2016","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.neurol.2020.02.011_bib0710","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1007\/s00415-015-7796-2","article-title":"Epidemiology of multiple sclerosis: results from a large observational study in the UK","volume":"262","author":"Jick","year":"2015","journal-title":"J Neurol"},{"key":"10.1016\/j.neurol.2020.02.011_bib0715","doi-asserted-by":"crossref","first-page":"221","DOI":"10.7224\/1537-2073.2014-035","article-title":"Multiple sclerosis and risk of infection-related hospitalization and death in US veterans","author":"Nelson","year":"2015","journal-title":"Int J MS Care"},{"issue":"3","key":"10.1016\/j.neurol.2020.02.011_bib0720","first-page":"359","article-title":"Recurrent urinary tract infections management in women: a review","volume":"13","author":"Al-Badr","year":"2013","journal-title":"Sultan Qaboos Univ Med J"},{"key":"10.1016\/j.neurol.2020.02.011_bib0725","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.medmal.2019.02.006","article-title":"Urinary tract infections in patients with neurogenic bladder","volume":"49","author":"Dinh","year":"2019","journal-title":"Med Mal Infect"},{"key":"10.1016\/j.neurol.2020.02.011_bib0730","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0003-9993(98)90003-X","article-title":"Vesicourethral dysfunction and urodynamic findings in multiple sclerosis: a study of 149 cases","volume":"79","author":"Gallien","year":"1998","journal-title":"Arch Phys Med Rehabil"},{"key":"10.1016\/j.neurol.2020.02.011_bib0735","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1590\/S1677-55382011000100003","article-title":"The urinary bladder and the rectum have a common embryological origin in the cloaca. The motor nerve supply of each is provided by the paraReview","volume":"37","author":"Averbeck","year":"2011","journal-title":"Int Braz J Urol"},{"key":"10.1016\/j.neurol.2020.02.011_bib0740","series-title":"Development of a good practice guidelines. \u201cFormal consensus\u201d Method","author":"HAS","year":"2010"},{"key":"10.1016\/j.neurol.2020.02.011_bib0745","series-title":"The RAND\/UCLA appropriateness method user's manual","author":"Rand Corporation","year":"2001"},{"key":"10.1016\/j.neurol.2020.02.011_bib0750","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1093\/brain\/awf098","article-title":"Prospective study on the relationship between infections and multiple sclerosis exacerbations","volume":"125","author":"Buljevac","year":"2002","journal-title":"Brain J Neurol"},{"key":"10.1016\/j.neurol.2020.02.011_bib0755","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1212\/01.wnl.0000233834.09743.3b","article-title":"The risk of relapses in multiple sclerosis during systemic infections","volume":"67","author":"Correale","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2020.02.011_bib0760","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/0736-4679(92)90333-O","article-title":"Functional urinary outlet obstruction causing urosepsis in a male multiple sclerosis patient","volume":"10","author":"Franz","year":"1992","journal-title":"J Emerg Med"},{"key":"10.1016\/j.neurol.2020.02.011_bib0765","first-page":"67","article-title":"Urinary tract infections may trigger relapse in multiple sclerosis","volume":"19","author":"Metz","year":"1998","journal-title":"Axone Dartm"},{"key":"10.1016\/j.neurol.2020.02.011_bib0770","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1177\/135245850000600608","article-title":"Neurological worsening due to infection from renal stones in a multiple sclerosis patient","volume":"6","author":"Hillman","year":"2000","journal-title":"Mult Scler"},{"key":"10.1016\/j.neurol.2020.02.011_bib0775","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S1474-4422(11)70262-9","article-title":"Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX): a phase 3 randomized controlled trial","volume":"11","author":"Comi","year":"2012","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.neurol.2020.02.011_bib0780","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1002\/ana.410390304","article-title":"Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis","volume":"39","author":"Jacobs","year":"1996","journal-title":"Ann Neurol"},{"issue":"9139","key":"10.1016\/j.neurol.2020.02.011_bib0785","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1016\/S0140-6736(98)03334-0","article-title":"Randomized double-blind placebo-controlled study of interferon \u03b2-1a in relapsing\/remitting multiple sclerosis","volume":"352","author":"Ebers","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.neurol.2020.02.011_bib0790","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/S1474-4422(14)70068-7","article-title":"Pegylated interferon beta-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study","volume":"13","author":"Calabresi","year":"2014","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.neurol.2020.02.011_bib0795","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.neurol.2018.03.012","article-title":"First-line therapy in relapsing remitting multiple sclerosis","volume":"174","author":"Biotti","year":"2018","journal-title":"Rev Neurol (Paris)"},{"key":"10.1016\/j.neurol.2020.02.011_bib0800","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1111\/ane.12712","article-title":"Safety concerns and risk management of multiple sclerosis therapies","volume":"136","author":"Soelberg-Sorensen","year":"2017","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.neurol.2020.02.011_bib0805","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1212\/WNL.45.7.1268","article-title":"Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial","volume":"45","author":"Johnson","year":"1995","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2020.02.011_bib0810","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1177\/135245850000600407","article-title":"Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years","volume":"6","author":"Johnson","year":"2000","journal-title":"Mult Scler"},{"key":"10.1016\/j.neurol.2020.02.011_bib0815","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/S1474-4422(08)70200-X","article-title":"Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial","volume":"7","author":"Mikol","year":"2008","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.neurol.2020.02.011_bib0820","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1191\/135248506ms1318oa","article-title":"A prospective open-label study of glatiramer acetate: over a decade of continuous use in multiple sclerosis patients","volume":"12","author":"Ford","year":"2006","journal-title":"Mult Scler J"},{"key":"10.1016\/j.neurol.2020.02.011_bib0825","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1177\/1352458512436594","article-title":"Long-term follow-up of a phase 2 study of oral teriflunomide in relapsing multiple sclerosis: safety and efficacy results up to 8.5 years","volume":"18","author":"Confavreux","year":"2012","journal-title":"Mult Scler"},{"key":"10.1016\/j.neurol.2020.02.011_bib0830","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/S1474-4422(14)70191-7","article-title":"Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis (TOPIC): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"13","author":"Miller","year":"2014","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.neurol.2020.02.011_bib0835","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1056\/NEJMoa1014656","article-title":"Randomized trial of oral teriflunomide for relapsing multiple sclerosis","volume":"365","author":"O\u2019Connor","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.neurol.2020.02.011_bib0840","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1177\/1352458513507821","article-title":"Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial","volume":"20","author":"Vermersch","year":"2014","journal-title":"Mult Scler"},{"key":"10.1016\/j.neurol.2020.02.011_bib0845","doi-asserted-by":"crossref","first-page":"e635","DOI":"10.1212\/WNL.0000000000007938","article-title":"Comparative effectiveness of teriflunomide vs dimethyl fumarate in multiple sclerosis","volume":"93","author":"Laplaud","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2020.02.011_bib0850","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1056\/NEJMoa1206328","article-title":"Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis","volume":"367","author":"Fox","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.neurol.2020.02.011_bib0855","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1177\/1352458516649037","article-title":"Long-term effects of delayed-release dimethyl fumarate in multiple sclerosis: interim analysis of ENDORSE, a randomized extension study","volume":"23","author":"Gold","year":"2017","journal-title":"Mult Scler"},{"key":"10.1016\/j.neurol.2020.02.011_bib0860","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1056\/NEJMoa1114287","article-title":"Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis","volume":"367","author":"Gold","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.neurol.2020.02.011_bib0865","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s40120-016-0042-8","article-title":"Sustained effect of delayed-release dimethyl fumarate in newly diagnosed patients with relapsing-remitting multiple sclerosis: 6-year interim results from an extension of the DEFINE and CONFIRM studies","volume":"5","author":"Gold","year":"2016","journal-title":"Neurol Ther"},{"key":"10.1016\/j.neurol.2020.02.011_bib0870","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1007\/s12325-018-0788-8","article-title":"72-week safety and tolerability of dimethyl fumarate in Japanese patients with relapsing-remitting multiple sclerosis: analysis of the randomised, double blind, placebo-controlled, phase III APEX study and its open-label extension","volume":"35","author":"Ochi","year":"2018","journal-title":"Adv Ther"},{"key":"10.1016\/j.neurol.2020.02.011_bib0875","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S1474-4422(14)70049-3","article-title":"Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"13","author":"Calabresi Peter","year":"2014","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.neurol.2020.02.011_bib0880","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1136\/jnnp-2015-310597","article-title":"Long-term (up to 4.5 years) treatment with fingolimod in multiple sclerosis: results from the extension of the randomized TRANSFORMS study","volume":"87","author":"Cohen","year":"2016","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.neurol.2020.02.011_bib0885","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1056\/NEJMoa0907839","article-title":"Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis","volume":"362","author":"Cohen","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.neurol.2020.02.011_bib0890","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1212\/WNL.0000000000001462","article-title":"Long-term effects of fingolimod in multiple sclerosis: the randomized FREEDOMS extension trial","volume":"84","author":"Kappos","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2020.02.011_bib0895","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.msard.2014.03.002","article-title":"Fingolimod in relapsing multiple sclerosis: an integrated analysis of safety findings","volume":"3","author":"Kappos","year":"2014","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.neurol.2020.02.011_bib0900","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1056\/NEJMoa0909494","article-title":"A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis","volume":"362","author":"Kappos","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.neurol.2020.02.011_bib0905","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s10072-016-2701-z","article-title":"Safety and tolerability of fingolimod in patients with relapsing-remitting multiple sclerosis: results of an open-label clinical trial in Italy","volume":"38","author":"Laroni","year":"2017","journal-title":"Neurol Sci"},{"key":"10.1016\/j.neurol.2020.02.011_bib0910","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1007\/s12325-015-0224-2","article-title":"Safety and tolerability of Fingolimod in Latin American patients with relapsing-remitting multiple sclerosis: the Open-Label FIRST LATAM Study","volume":"32","author":"Ordo\u00f1ez-Boschetti","year":"2015","journal-title":"Adv Ther"},{"key":"10.1016\/j.neurol.2020.02.011_bib0915","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.jneuroim.2015.10.015","article-title":"Safety and efficacy of fingolimod in clinical practice: the experience of an academic center in the Middle East","volume":"289","author":"Yamout","year":"2015","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.neurol.2020.02.011_bib0920","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1056\/NEJMoa0902533","article-title":"A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis","volume":"362","author":"Giovannoni","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.neurol.2020.02.011_bib0925","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S1474-4422(14)70005-5","article-title":"Effect of oral cladribine on time to conversion to clinically definite multiple sclerosis in patients with a first demyelinating event (ORACLE MS): a phase 3 randomised trial","volume":"13","author":"Leist","year":"2014","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.neurol.2020.02.011_bib0930","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1177\/1352458517727603","article-title":"Safety and efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis: results from the randomized extension trial of the CLARITY study","volume":"24","author":"Giovannoni","year":"2018","journal-title":"Mult Scler"},{"key":"10.1016\/j.neurol.2020.02.011_bib0935","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.msard.2018.11.021","article-title":"Safety of cladribine tablets in the treatment of patients with multiple sclerosis: an integrated analysis","volume":"29","author":"Cook","year":"2019","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.neurol.2020.02.011_bib0940","doi-asserted-by":"crossref","first-page":"e477","DOI":"10.1212\/NXI.0000000000000477","article-title":"Cladribine tablets added to IFN-\u03b2 in active relapsing MS: the ONWARD study","volume":"5","author":"Montalban","year":"2018","journal-title":"Neurol Neuroimmunol Neuroinflammation"},{"key":"10.1016\/j.neurol.2020.02.011_bib0945","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s004150050066","article-title":"Randomized placebo-controlled trial of mitoxantrone in relapsing-remitting multiple sclerosis: 24-month clinical and MRI outcome","volume":"244","author":"Millefiorini","year":"1997","journal-title":"J Neurol"},{"key":"10.1016\/j.neurol.2020.02.011_bib0950","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1136\/jnnp.62.2.112","article-title":"Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria","volume":"62","author":"Edan","year":"1997","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.neurol.2020.02.011_bib0955","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1016\/S0140-6736(02)12023-X","article-title":"Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial","volume":"360","author":"Hartung","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.neurol.2020.02.011_bib0960","first-page":"5","article-title":"Mitoxantrone for multiple sclerosis","author":"Boneschi","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.neurol.2020.02.011_bib0965","first-page":"12","article-title":"A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis","author":"Polman","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.neurol.2020.02.011_bib0970","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1056\/NEJMoa044396","article-title":"Natalizumab plus interferon beta-1a for relapsing multiple sclerosis","volume":"354","author":"Rudick","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.neurol.2020.02.011_bib0975","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/S1474-4422(18)30069-3","article-title":"Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomized, double-blind, placebo-controlled trial with an open-label extension","volume":"17","author":"Kapoor","year":"2018","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.neurol.2020.02.011_bib0980","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.msard.2018.07.024","article-title":"Gynecological adverse effects of natalizumab administration: case report and review of the literature","volume":"25","author":"Makris","year":"2018","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.neurol.2020.02.011_bib0985","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1056\/NEJMoa0802670","article-title":"Alemtuzumab vs. interferon beta-1a in early multiple sclerosis","volume":"359","author":"CAMMS223 Trial Investigators","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.neurol.2020.02.011_bib0990","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/S0140-6736(12)61769-3","article-title":"Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomized controlled phase 3 trial","volume":"380","author":"Cohen","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.neurol.2020.02.011_bib0995","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1016\/S0140-6736(12)61768-1","article-title":"Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomized controlled phase 3 trial","volume":"380","author":"Coles","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.neurol.2020.02.011_bib1000","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1177\/1352458518796675","article-title":"Infection risk with alemtuzumab decreases over time: pooled analysis of 6-year data from the CAMMS223, CARE-MS I, and CARE-MS II studies and the CAMMS03409 extension study","volume":"25","author":"Wray","year":"2019","journal-title":"Mult Scler J"},{"key":"10.1016\/j.neurol.2020.02.011_bib1005","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa1601277","article-title":"Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis","volume":"376","author":"Hauser","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.neurol.2020.02.011_bib1010","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1056\/NEJMoa1606468","article-title":"Ocrelizumab versus placebo in primary progressive multiple sclerosis","volume":"376","author":"Montalban","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.neurol.2020.02.011_bib1015","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1016\/S0140-6736(11)61649-8","article-title":"Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial","volume":"378","author":"Kappos","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.neurol.2020.02.011_bib1020","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1191\/1352458505ms1210oa","article-title":"A randomized blinded trial of combination therapy with cyclophosphamide in patients with active multiple sclerosis on interferon beta","volume":"11","author":"Smith","year":"2005","journal-title":"Mult Scler J"},{"key":"10.1016\/j.neurol.2020.02.011_bib1025","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD002819.pub2","article-title":"Cyclophosphamide for multiple sclerosis","author":"La Mantia","year":"2007","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.neurol.2020.02.011_bib1030","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1191\/1352458503ms926oa","article-title":"Safety and tolerability of cyclophosphamide \u2018pulses\u2019 in multiple sclerosis: a prospective study in a clinical cohort","volume":"9","author":"Portaccio","year":"2003","journal-title":"Mult Scler J"},{"key":"10.1016\/j.neurol.2020.02.011_bib1035","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1007\/s00415-005-0857-1","article-title":"The combination of cyclophosphamide plus interferon beta as rescue therapy could be used to treat relapsing\u2013remitting multiple sclerosis patients: twenty-four months follow-up","volume":"252","author":"Reggio","year":"2005","journal-title":"J Neurol"},{"key":"10.1016\/j.neurol.2020.02.011_bib1040","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1177\/1756285609353354","article-title":"A randomized, blinded, parallel-group, pilot trial of mycophenolate mofetil (CellCept) compared with interferon beta-1a (Avonex) in patients with relapsing-remitting multiple sclerosis","volume":"3","author":"Frohman","year":"2010","journal-title":"Ther Adv Neurol Disord"},{"key":"10.1016\/j.neurol.2020.02.011_bib1045","first-page":"1","article-title":"Mycophenolate mofetil in combination with interferon beta-1a in the treatment of relapsing-remitting multiple sclerosis: a preliminary study","volume":"16","author":"Etemadifar","year":"2011","journal-title":"J Res Med Sci"},{"key":"10.1016\/j.neurol.2020.02.011_bib1050","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1177\/1756285609355851","article-title":"A one-year prospective, randomized, placebo-controlled, quadruple-blinded, phase II safety pilot trial of combination therapy with interferon beta-1a and mycophenolate mofetil in early relapsing\u2014remitting multiple sclerosis (TIME MS)","volume":"3","author":"Remington","year":"2010","journal-title":"Ther Adv Neurol Disord"},{"key":"10.1016\/j.neurol.2020.02.011_bib1055","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1111\/j.1468-1331.2006.01562.x","article-title":"Combination of IFN?-1a (Avonex\u00ae) and mycophenolate mofetil (Cellcept\u00ae) in multiple sclerosis","volume":"14","author":"Vermersch","year":"2007","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.neurol.2020.02.011_bib1060","doi-asserted-by":"crossref","first-page":"2688","DOI":"10.1007\/s00415-018-9050-1","article-title":"Efficacy and safety of mycophenolate mofetil in progressive multiple sclerosis patients","volume":"265","author":"Fakih","year":"2018","journal-title":"J Neurol"},{"key":"10.1016\/j.neurol.2020.02.011_bib1065","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1136\/jnnp-2013-305298","article-title":"Mycophenolate mofetil in multiple sclerosis: a multicentre retrospective study on 344 patients","volume":"85","author":"Michel","year":"2014","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.neurol.2020.02.011_bib1070","doi-asserted-by":"crossref","first-page":"e113371","DOI":"10.1371\/journal.pone.0113371","article-title":"Azathioprine versus beta interferons for relapsing-remitting multiple sclerosis: a multicentre randomized non-inferiority trial","volume":"9","author":"Massacesi","year":"2014","journal-title":"PLoS ONE"},{"key":"10.1016\/j.neurol.2020.02.011_bib1075","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1177\/1352458509105229","article-title":"Randomized study of interferon beta-1a, low-dose azathioprine, and low-dose corticosteroids in multiple sclerosis","volume":"15","author":"Havrdova","year":"2009","journal-title":"Mult Scler J"},{"key":"10.1016\/j.neurol.2020.02.011_bib1080","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/j.clineuro.2012.02.014","article-title":"Interferon, azathioprine and corticosteroids in multiple sclerosis: 6-year follow-up of the ASA cohort","volume":"114","author":"Kalincik","year":"2012","journal-title":"Clin Neurol Neurosurg"},{"key":"10.1016\/j.neurol.2020.02.011_bib1085","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1179\/1743132812Y.0000000090","article-title":"Interferon-beta or azathioprine as add-on therapies in patients with active multiple sclerosis","volume":"34","author":"Ticha","year":"2012","journal-title":"Neurol Res"},{"key":"10.1016\/j.neurol.2020.02.011_bib1090","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s10072-007-0842-9","article-title":"Azathioprine. Safety profile in multiple sclerosis patients","volume":"28","author":"La Mantia","year":"2007","journal-title":"Neurol Sci"},{"key":"10.1016\/j.neurol.2020.02.011_bib1095","first-page":"4","article-title":"Azathioprine for multiple sclerosis","author":"Casetta","year":"2007","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.neurol.2020.02.011_bib1100","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1002\/ana.21867","article-title":"Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial","volume":"66","author":"Hawker","year":"2009","journal-title":"Ann Neurol"},{"key":"10.1016\/j.neurol.2020.02.011_bib1105","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1056\/NEJMoa0706383","article-title":"B-Cell depletion with rituximab in relapsing\u2013remitting multiple sclerosis","volume":"358","author":"Hauser","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.neurol.2020.02.011_bib1110","article-title":"Experience with long-term rituximab use in a multiple sclerosis clinic","volume":"2","author":"Barra","year":"2016","journal-title":"Mult Scler"},{"key":"10.1016\/j.neurol.2020.02.011_bib1115","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1212\/WNL.0000000000003331","article-title":"Rituximab in multiple sclerosis: a retrospective observational study on safety and efficacy","volume":"87","author":"Salzer","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2020.02.011_bib1120","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1002\/ana.21363","article-title":"Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, phase I trial","volume":"63","author":"Bar-Or","year":"2008","journal-title":"Ann Neurol"},{"key":"10.1016\/j.neurol.2020.02.011_bib1125","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s12288-016-0661-3","article-title":"Therapeutic plasma exchange in patients with neurologic disorders: review of 63 cases","volume":"33","author":"Tombak","year":"2017","journal-title":"Indian J Hematol Blood Transfus"},{"key":"10.1016\/j.neurol.2020.02.011_bib1130","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1002\/1531-8249(199912)46:6<878::AID-ANA10>3.0.CO;2-Q","article-title":"A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease","volume":"46","author":"Weinshenker","year":"1999","journal-title":"Ann Neurol"},{"key":"10.1016\/j.neurol.2020.02.011_bib1135","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1111\/1744-9987.12176","article-title":"Therapeutic plasma exchange in glucocorticosteroid-unresponsive patients with Clinically Isolated Syndrome","volume":"18","author":"Ehler","year":"2014","journal-title":"Ther Apher Dial"},{"key":"10.1016\/j.neurol.2020.02.011_bib1140","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1111\/j.1537-2995.2004.04154.x","article-title":"Complications of double-filtration plasmapheresis","volume":"44","author":"Yeh","year":"2004","journal-title":"Transfusion (Paris)"},{"key":"10.1016\/j.neurol.2020.02.011_bib1145","first-page":"349","article-title":"Randomised trial of oral and intravenous methylprednisolone in acute relapses of multiple sclerosis","author":"Barnes","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/j.neurol.2020.02.011_bib1150","first-page":"1","article-title":"Corticosteroids for the long-term treatment in multiple sclerosis","author":"Ciccone","year":"2008","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.neurol.2020.02.011_bib1155","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/S0140-6736(15)61137-0","article-title":"Oral versus intravenous high-dose methylprednisolone for treatment of relapses in patients with multiple sclerosis (COPOUSEP): a randomised, controlled, double-blind, non-inferiority trial","volume":"386","author":"Le Page","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.neurol.2020.02.011_bib1160","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.clineuro.2017.06.016","article-title":"Monthly methylprednisolone in combination with interferon beta or glatiramer acetate for relapsing-remitting multiple sclerosis: a multicentre, single-blind, prospective trial","volume":"160","author":"Ozakbas","year":"2017","journal-title":"Clin Neurol Neurosurg"},{"key":"10.1016\/j.neurol.2020.02.011_bib1165","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1136\/jnnp.51.2.285","article-title":"Methylprednisolone therapy in multiple sclerosis: a profile of adverse effects","volume":"51","author":"Lyons","year":"1988","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.neurol.2020.02.011_bib1170","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1111\/j.1468-1331.2012.03806.x","article-title":"Testing for urinary tract colonization before high-dose corticosteroid treatment in acute multiple sclerosis relapses: prospective algorithm validation","volume":"20","author":"Rakusa","year":"2013","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.neurol.2020.02.011_bib1175","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.neurol.2015.04.013","article-title":"To treat or not to treat asymptomatic bacteriuria before methylprednisolone perfusion","volume":"171","author":"Donz\u00e9","year":"2015","journal-title":"Rev Neurol"},{"key":"10.1016\/j.neurol.2020.02.011_bib1180","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/S0140-6736(09)60442-6","article-title":"Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial","volume":"373","author":"Goodman","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.neurol.2020.02.011_bib1185","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1080\/00325481.2015.1000229","article-title":"Assessment of confirmed urinary tract infection in patients treated with dalfampridine for multiple sclerosis","volume":"127","author":"Kantor","year":"2015","journal-title":"Postgrad Med"},{"key":"10.1016\/j.neurol.2020.02.011_bib1190","doi-asserted-by":"crossref","first-page":"169","DOI":"10.2147\/DHPS.S97113","article-title":"Safety profile of dalfampridine extended release in multiple sclerosis: 5-year postmarketing experience in the United States","author":"Jara","year":"2015","journal-title":"Drug Healthc Patient Saf"},{"key":"10.1016\/j.neurol.2020.02.011_bib1195","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2019\/2757862","article-title":"Adult neurogenic lower urinary tract dysfunction and intermittent catheterisation in a community setting: risk factors model for urinary tract infections","author":"Kennelly","year":"2019","journal-title":"Adv Urol"},{"key":"10.1016\/j.neurol.2020.02.011_bib1200","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.msard.2019.06.038","article-title":"The prevalence and utility of screening for urinary tract infection at the time of presumed multiple sclerosis relapse","volume":"35","author":"Fitzgerald","year":"2019","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.neurol.2020.02.011_bib1205","doi-asserted-by":"crossref","first-page":"120","DOI":"10.5539\/gjhs.v8n4p253","article-title":"Association between urinary symptoms and urinary tract infection in patients with multiple sclerosis","volume":"8","author":"Nikseresht","year":"2015","journal-title":"Glob J Health Sci"},{"key":"10.1016\/j.neurol.2020.02.011_bib1210","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1177\/1352458513517592","article-title":"Cranberry versus placebo in the prevention of urinary infections in multiple sclerosis: a multicenter, randomized, placebo-controlled, double-blind trial","volume":"20","author":"Gallien","year":"2014","journal-title":"Mult Scler"},{"key":"10.1016\/j.neurol.2020.02.011_bib1215","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1053\/apmr.2002.26605","article-title":"Antimicrobial prophylaxis for urinary tract infection in persons with spinal cord dysfunction","volume":"83","author":"Morton","year":"2002","journal-title":"Arch Phys Med Rehabil"},{"key":"10.1016\/j.neurol.2020.02.011_bib1220","first-page":"CD004201","article-title":"Urinary catheter policies for long-term bladder drainage","volume":"8","author":"Ni\u00ebl-Weise","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.neurol.2020.02.011_bib1225","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1093\/jac\/dkl010","article-title":"Prevention of urinary tract infection in spinal cord-injured patients: safety and efficacy of a weekly oral cyclic antibiotics (WOCA) program with a 2 year follow-up\u2014An observational prospective study","volume":"57","author":"Salomon","year":"2006","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.neurol.2020.02.011_bib1230","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.medmal.2016.02.010","article-title":"Prevention of urinary tract infections by antibiotic cycling in spinal cord injury patients and low emergence of multidrug resistant bacteria","volume":"46","author":"Poirier","year":"2016","journal-title":"Med Mal Infect"},{"key":"10.1016\/j.neurol.2020.02.011_bib1235","doi-asserted-by":"crossref","first-page":"827","DOI":"10.7326\/0003-4819-120-10-199405150-00003","article-title":"Does asymptomatic bacteriuria predict mortality and does antimicrobial treatment reduce mortality in elderly ambulatory women?","volume":"120","author":"Abrutyn","year":"1994","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.neurol.2020.02.011_bib1240","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/0002-9343(87)90493-1","article-title":"Prospective randomized comparison of therapy and no therapy for asymptomatic bacteriuria in institutionalized elderly women","volume":"83","author":"Nicolle","year":"1987","journal-title":"Am J Med"},{"key":"10.1016\/j.neurol.2020.02.011_bib1245","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/0090-4295(84)90136-5","article-title":"Significance of asymptomatic bacteriuria in neurogenic bladder disease","volume":"23","author":"Lewis","year":"1984","journal-title":"Urology"},{"key":"10.1016\/j.neurol.2020.02.011_bib1250","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/S0022-5347(17)43138-7","article-title":"Suppression and treatment of urinary tract infection in patients with an intermittently catheterized neurogenic bladder","volume":"138","author":"Mohler","year":"1987","journal-title":"J Urol"},{"key":"10.1016\/j.neurol.2020.02.011_bib1255","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1038\/sc.1993.104","article-title":"Eradication of urinary tract infection following spinal cord injury","volume":"31","author":"Waites","year":"1993","journal-title":"Spinal Cord"},{"key":"10.1016\/j.neurol.2020.02.011_bib1260","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1179\/joc.2010.22.1.36","article-title":"Effects of antimicrobial prophylaxis on asymptomatic bacteriuria and predictors of failure in patients with multiple sclerosis","volume":"22","author":"Fakas","year":"2010","journal-title":"J Chemother"},{"key":"10.1016\/j.neurol.2020.02.011_bib1265","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1136\/jnnp.2008.159178","article-title":"A UK consensus on the management of the bladder in multiple sclerosis","volume":"85","author":"Fowler","year":"2009","journal-title":"Postgrad Med J"},{"key":"10.1016\/j.neurol.2020.02.011_bib1270","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1086\/427507","article-title":"Infectious Diseases Society of America guidelines for the diagnosis and treatment of asymptomatic bacteriuria in adults","volume":"40","author":"Nicolle","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.neurol.2020.02.011_bib1275","doi-asserted-by":"crossref","first-page":"4","DOI":"10.3390\/pathogens5010004","article-title":"Asymptomatic bacteriuria in clinical urological practice: preoperative control of bacteriuria and management of recurrent UTI","volume":"5","author":"Cai","year":"2016","journal-title":"Pathogens"},{"issue":"6","key":"10.1016\/j.neurol.2020.02.011_bib1280","first-page":"985","article-title":"Asymptomatic bacteriuria in adults","volume":"74","author":"Colgan","year":"2006","journal-title":"Am Fam Physician"},{"key":"10.1016\/j.neurol.2020.02.011_bib1285","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1002\/nau.23253","article-title":"Best practice policy statement on urodynamic antibiotic prophylaxis in the non-index patient","volume":"36","author":"Cameron","year":"2017","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.neurol.2020.02.011_bib1290","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/j.purol.2018.10.001","article-title":"Antibiotic prophylaxis in urodynamics: clinical practice guidelines using a formal consensus method","volume":"28","author":"Egrot","year":"2018","journal-title":"Prog Urol"},{"key":"10.1016\/j.neurol.2020.02.011_bib1295","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/sc.2012.107","article-title":"Morbidity of urinary tract infection after urodynamic examination of hospitalized SCI patients: the impact of bladder management","volume":"51","author":"B\u00f6thig","year":"2013","journal-title":"Spinal Cord"},{"key":"10.1016\/j.neurol.2020.02.011_bib1300","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/0195-6701(94)90153-8","article-title":"Antibiotic prophylaxis for urodynamic testing in patients with spinal cord injury: a preliminary study","volume":"28","author":"Darouiche","year":"1994","journal-title":"J Hosp Infect"},{"key":"10.1016\/j.neurol.2020.02.011_bib1305","first-page":"390","article-title":"Urodynamics: the incidence of urinary tract infection and autonomic dysreflexia in a challenging population","volume":"24","author":"Joseph","year":"2004","journal-title":"Urol Nurs"},{"key":"10.1016\/j.neurol.2020.02.011_bib1310","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.medmal.2016.04.001","article-title":"Prospective evaluation of antibiotic treatment for urological procedure in patients presenting with neurogenic bladder","volume":"46","author":"Weglinski","year":"2016","journal-title":"Med Mal Infect"},{"key":"10.1016\/j.neurol.2020.02.011_bib1315","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1038\/sj.sc.3102114","article-title":"Morbidity of urodynamic testing in patients with spinal cord injury: is antibiotic prophylaxis necessary?","volume":"45","author":"Pannek","year":"2007","journal-title":"Spinal Cord"},{"key":"10.1016\/j.neurol.2020.02.011_bib1320","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/S1473-3099(18)30279-2","article-title":"Continuous low-dose antibiotic prophylaxis for adults with repeated urinary tract infections (AnTIC): a randomised, open-label trial","volume":"18","author":"Fisher","year":"2018","journal-title":"Lancet Infect Dis"}],"container-title":["Revue Neurologique"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0035378720306172?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0035378720306172?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T05:41:21Z","timestamp":1758519681000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0035378720306172"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":132,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["S0035378720306172"],"URL":"https:\/\/doi.org\/10.1016\/j.neurol.2020.02.011","relation":{},"ISSN":["0035-3787"],"issn-type":[{"value":"0035-3787","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Urinary tract infections and multiple sclerosis: Recommendations from the French Multiple Sclerosis Society","name":"articletitle","label":"Article Title"},{"value":"Revue Neurologique","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neurol.2020.02.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}